Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Distress, problems, referral wish, and supportive health care use in breast cancer survivors beyond the first year after chemotherapy completion.

Admiraal JM, Hoekstra-Weebers JEHM, Schröder CP, Tuinier W, Hospers GAP, Reyners AKL.

Support Care Cancer. 2019 Sep 11. doi: 10.1007/s00520-019-05030-6. [Epub ahead of print]

PMID:
31511981
2.

Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis?

Venema CM, de Vries EFJ, van der Veen SJ, Dorrius MD, van Kruchten M, Schröder CP, Hospers GAP, Glaudemans AWJM.

EJNMMI Res. 2019 Aug 23;9(1):82. doi: 10.1186/s13550-019-0549-y.

3.

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.

van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP.

Am J Surg Pathol. 2019 Oct;43(10):1355-1360. doi: 10.1097/PAS.0000000000001321.

PMID:
31283631
4.

Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis.

Jauw YWS, Bensch F, Brouwers AH, Hoekstra OS, Zijlstra JM, Pieplenbosch S, Schröder CP, Zweegman S, van Dongen GAMS, Menke-van der Houven van Oordt CW, de Vries EGE, de Vet HCW, Boellaard R, Huisman MC.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1840-1849. doi: 10.1007/s00259-019-04377-6. Epub 2019 Jun 17.

5.

Consideration of breast cancer subtype in targeting the androgen receptor.

Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE.

Pharmacol Ther. 2019 Aug;200:135-147. doi: 10.1016/j.pharmthera.2019.05.005. Epub 2019 May 8. Review.

6.

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.

Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJA, de Vries EGE.

Clin Cancer Res. 2019 Jun 15;25(12):3517-3527. doi: 10.1158/1078-0432.CCR-18-2918. Epub 2019 Feb 11.

PMID:
30745297
7.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.

PMID:
30478423
8.

Tumor-associated macrophages in breast cancer: Innocent bystander or important player?

Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP.

Cancer Treat Rev. 2018 Nov;70:178-189. doi: 10.1016/j.ctrv.2018.08.010. Epub 2018 Aug 28. Review.

9.

Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse.

Bensch F, Smeenk MM, van Es SC, de Jong JR, Schröder CP, Oosting SF, Lub-de Hooge MN, Menke-van der Houven van Oordt CW, Brouwers AH, Boellaard R, de Vries EGE.

Theranostics. 2018 Jul 30;8(16):4295-4304. doi: 10.7150/thno.26370. eCollection 2018.

10.

Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer.

van Rooijen JM, Qiu SQ, Timmer-Bosscha H, van der Vegt B, Boers JE, Schröder CP, de Vries EGE.

Eur J Cancer. 2018 Nov;103:52-60. doi: 10.1016/j.ejca.2018.08.001. Epub 2018 Sep 9.

PMID:
30208359
11.

SLAP lesions, An Opinion Piece.

Schrøder CP.

Open Orthop J. 2018 Jul 31;12:342-345. doi: 10.2174/1874325001812010342. eCollection 2018. Review.

12.

Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.

Bense RD, Qiu SQ, de Vries EGE, Schröder CP, Fehrmann RSN.

Cancer Treat Rev. 2018 Nov;70:118-126. doi: 10.1016/j.ctrv.2018.07.015. Epub 2018 Jul 26. Review.

13.

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.

Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2300-2306. doi: 10.1007/s00259-018-4099-8. Epub 2018 Jul 30.

14.

Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery.

Qiu SQ, Dorrius MD, de Jongh SJ, Jansen L, de Vries J, Schröder CP, Zhang GJ, de Vries EGE, van der Vegt B, van Dam GM.

Eur J Surg Oncol. 2018 Nov;44(11):1708-1713. doi: 10.1016/j.ejso.2018.06.022. Epub 2018 Jul 3.

PMID:
30005963
15.

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors.

Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga AGTT, Schröder CP, de Vries EGE, Lub-de Hooge MN.

Clin Cancer Res. 2018 Oct 15;24(20):4988-4996. doi: 10.1158/1078-0432.CCR-18-0786. Epub 2018 Jul 6.

16.

18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Nienhuis HH, van Kruchten M, Elias SG, Glaudemans AWJM, de Vries EFJ, Bongaerts AHH, Schröder CP, de Vries EGE, Hospers GAP.

J Nucl Med. 2018 Aug;59(8):1212-1218. doi: 10.2967/jnumed.117.198846. Epub 2018 Mar 30.

17.

Evolution in sentinel lymph node biopsy in breast cancer.

Qiu SQ, Zhang GJ, Jansen L, de Vries J, Schröder CP, de Vries EGE, van Dam GM.

Crit Rev Oncol Hematol. 2018 Mar;123:83-94. doi: 10.1016/j.critrevonc.2017.09.010. Epub 2017 Sep 20. Review.

PMID:
29482783
18.

Paralabral cysts of the shoulder treated with isolated labral repair: effect on pain and radiologic findings.

Schrøder CP, Lundgreen K, Kvakestad R.

J Shoulder Elbow Surg. 2018 Jul;27(7):1283-1289. doi: 10.1016/j.jse.2017.12.022. Epub 2018 Feb 13.

PMID:
29449084
19.

Molecular Imaging in Cancer Drug Development.

Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE.

J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25. Review.

20.

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.

Han SN, Amant F, Cardonick EH, Loibl S, Peccatori FA, Gheysens O, Sangalli CA, Nekljudova V, Steffensen KD, Mhallem Gziri M, Schröder CP, Lok CAR, Verest A, Neven P, Smeets A, Pruneri G, Cremonesi M, Gentilini O; International Network on Cancer, Infertility and Pregnancy.

Breast Cancer Res Treat. 2018 Apr;168(2):551-557. doi: 10.1007/s10549-017-4611-z. Epub 2017 Dec 12.

PMID:
29235045
21.

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP.

J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14.

22.

Author response-sham surgery versus labral repair or biceps tenodesis for type II SLAP lesions of the shoulder: a three-armed randomised clinical trial.

Brox JI, Schrøder CP, Skare Ø, Mowinckel P, Reikerås O.

Br J Sports Med. 2017 Dec;51(24):1778-1779. doi: 10.1136/bjsports-2017-098251. Epub 2017 Aug 17. No abstract available.

PMID:
28818958
23.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE.

Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21.

24.

Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: A Multicenter Randomized Controlled Trial.

Admiraal JM, van der Velden AWG, Geerling JI, Burgerhof JGM, Bouma G, Walenkamp AME, de Vries EGE, Schröder CP, Reyners AKL.

J Pain Symptom Manage. 2017 Oct;54(4):466-475. doi: 10.1016/j.jpainsymman.2017.07.009. Epub 2017 Jul 13.

PMID:
28711750
25.

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

Moghadasi S, Grundeken V, Janssen LAM, Dijkstra NH, Rodríguez-Girondo M, van Zelst-Stams WAG, Oosterwijk JC, Ausems MGEM, Oldenburg RA, Adank MA, Blom EW, Ruijs MWG, van Os TAM, van Deurzen CHM, Martens JWM, Schroder CP, Wijnen JT, Vreeswijk MPG, van Asperen CJ.

Clin Genet. 2018 Jan;93(1):52-59. doi: 10.1111/cge.13065. Epub 2017 Sep 25.

PMID:
28589637
26.

Sham surgery versus labral repair or biceps tenodesis for type II SLAP lesions of the shoulder: a three-armed randomised clinical trial.

Schrøder CP, Skare Ø, Reikerås O, Mowinckel P, Brox JI.

Br J Sports Med. 2017 Dec;51(24):1759-1766. doi: 10.1136/bjsports-2016-097098. Epub 2017 May 11.

27.

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM.

Eur J Cancer. 2017 Sep;82:219-227. doi: 10.1016/j.ejca.2017.01.034. Epub 2017 Mar 11.

PMID:
28292559
28.

Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.

Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM.

Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9.

29.

Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Dinjens WN, van Marion R, van Diest PJ, Martens JW, van Deurzen CH.

Mod Pathol. 2017 Apr;30(4):509-518. doi: 10.1038/modpathol.2016.229. Epub 2017 Jan 13.

30.

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.

de Waal EGM, Glaudemans AWJM, Schröder CP, Vellenga E, Slart RHJA.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):332-341. doi: 10.1007/s00259-016-3576-1. Epub 2016 Nov 29. Review.

31.

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.

Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, Kranendonk ME, Terwisscha van Scheltinga AG, Aichler M, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WP, Van der Wall E, Garcia-Allende PB, van Diest PJ, de Vries EG, Walch A, van Dam GM, Ntziachristos V.

Cancer Res. 2017 Feb 1;77(3):623-631. doi: 10.1158/0008-5472.CAN-16-1773. Epub 2016 Nov 22.

32.

Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.

Venema CM, Apollonio G, Hospers GA, Schröder CP, Dierckx RA, de Vries EF, Glaudemans AW.

Clin Nucl Med. 2016 Nov;41(11):844-851. Review.

PMID:
27607175
33.

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JBAG, van Vugt MATM, de Vries EGE, Schröder CP, Fehrmann RSN.

J Natl Cancer Inst. 2016 Oct 13;109(1). doi: 10.1093/jnci/djw192. Print 2017 Jan.

34.

Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal C, de Groot DJ, Schröder CP, Hospers GA, Brouwer E.

Rheumatology (Oxford). 2016 Jun;55(6):1143-5. doi: 10.1093/rheumatology/kew063. Epub 2016 Apr 11. No abstract available.

PMID:
27069016
35.

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.

van Es SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, Elias SG, Boellaard R, Hospers GA, Schröder CP, de Vries EG.

J Nucl Med. 2016 Feb;57 Suppl 1:96S-104S. doi: 10.2967/jnumed.115.157974. Review.

36.

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.

Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG.

Oncotarget. 2016 Apr 19;7(16):21247-58. doi: 10.18632/oncotarget.6918. Review.

37.

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P.

Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23.

PMID:
26598545
38.

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AH, Lub-de Hooge MN, Verheul HM, Sanabria Bohorquez SM, Glaudemans AW, de Vries EG.

Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20.

39.

Immunotherapeutic options on the horizon in breast cancer treatment.

van Rooijen JM, Stutvoet TS, Schröder CP, de Vries EG.

Pharmacol Ther. 2015 Dec;156:90-101. doi: 10.1016/j.pharmthera.2015.09.003. Epub 2015 Sep 24. Review.

PMID:
26388292
40.

Human stromal cells are required for an anti-breast cancer effect of zoledronic acid.

Nienhuis HH, Arjaans M, Timmer-Bosscha H, de Vries EG, Schröder CP.

Oncotarget. 2015 Sep 15;6(27):24436-47.

41.

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.

van Kruchten M, Glaudemans AWJM, de Vries EFJ, Schröder CP, de Vries EGE, Hospers GAP.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1674-1681. doi: 10.1007/s00259-015-3107-5. Epub 2015 Jun 20.

42.

BMI and lifetime changes in BMI and cancer mortality risk.

Taghizadeh N, Boezen HM, Schouten JP, Schröder CP, Elisabeth de Vries EG, Vonk JM.

PLoS One. 2015 Apr 16;10(4):e0125261. doi: 10.1371/journal.pone.0125261. eCollection 2015.

43.

Antibody positron emission tomography imaging in anticancer drug development.

Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schröder CP, Gietema JA, Brouwers AH, de Vries EG.

J Clin Oncol. 2015 May 1;33(13):1491-504. doi: 10.1200/JCO.2014.57.8278. Epub 2015 Mar 16. Review.

PMID:
25779566
44.

Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: a literature analysis.

Bouma G, Admiraal JM, de Vries EG, Schröder CP, Walenkamp AM, Reyners AK.

Crit Rev Oncol Hematol. 2015 Jul;95(1):26-37. doi: 10.1016/j.critrevonc.2015.01.011. Epub 2015 Jan 31. Review.

PMID:
25701515
45.

A 21-year-old patient with a HER2-positive colorectal cancer.

Bensch F, van Rooijen JM, Schröder CP, Reyners AK.

Gastroenterology. 2015 Jan;148(1):20-1. doi: 10.1053/j.gastro.2014.09.046. Epub 2014 Nov 5. No abstract available.

PMID:
25447849
46.

Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.

Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP.

Pharmacol Ther. 2015 Mar;147:63-79. doi: 10.1016/j.pharmthera.2014.11.004. Epub 2014 Nov 6. Review.

PMID:
25444756
47.

Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van Faassen M, Kema IP, Brown M, Schröder CP, de Vries EF, Hospers GA.

Cancer Discov. 2015 Jan;5(1):72-81. doi: 10.1158/2159-8290.CD-14-0697. Epub 2014 Nov 7.

48.

Responsiveness of outcome measures in patients with superior labral anterior and posterior lesions.

Skare Ø, Mowinckel P, Schrøder CP, Liavaag S, Reikerås O, Brox JI.

Shoulder Elbow. 2014 Oct;6(4):262-72. doi: 10.1177/1758573214534650. Epub 2014 May 27.

49.

89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.

Gaykema SB, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, Bongaerts AH, Akimov M, Fernandez-Ibarra C, Lub-de Hooge MN, de Vries EG, Swanton C, Banerji U.

Clin Cancer Res. 2014 Aug 1;20(15):3945-54. doi: 10.1158/1078-0432.CCR-14-0491.

50.

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SB, Lub-de Hooge MN, Kosterink JG, de Vries EG, Schröder CP.

Eur J Cancer. 2014 Sep;50(14):2508-16. doi: 10.1016/j.ejca.2014.06.008. Epub 2014 Jul 12.

PMID:
25027745

Supplemental Content

Loading ...
Support Center